Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artesunate Suppositories for High-Grade AIN
NCT03100045Phase 1Completed
- Sponsor
- Johns Hopkins University
- Start
- Apr 2017
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of artesunate in anal intraepithelial neoplasia (AIN) (6 arms), sponsored by Johns Hopkins University. Primary endpoint: Incidence of treatment-emergent adverse events at 6 weeks. Started Apr 2017; status: completed.
02
Drugs
artesunate
03
Conditions
anal intraepithelial neoplasia (AIN)
Beyond the preview
Go deeper on NCT03100045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03100045.